Papers, explained in our own words

25. Polymer Nanoparticles Containing Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell–Based Antitumor Immunotherapy

Shashi Prasad, Virginia Cody, Jennifer K. Saucier-Sawyer, W. Mark Saltzman, Clarence T. Sasaki, Richard L. Edelson, Martin A. Birchall, Douglas J. Hanlon

Efficient antigen delivery remains a major challenge for dendritic cell (DC)-based immunotherapy of solid-organ malignancies. Soluble tumour lysates suffer from instability, poor DC internalisation, and inefficient cross-presentation to cytotoxic T lymphocytes. PLGA nanoparticles may protect antigens, improve…

• Nanoparticles
• Polymeric
• T cells
• PLGA
• Dendritic cells
• Nanocarriers
• Gene delivery

26. Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles

Samar Hamdy, Azita Haddadi, Anooshirvan Shayeqanpour, John Samuel, Afsaneh Lavasanifar

Mannosylation of vaccine formulations is a promising strategy to target antigens to the mannose receptor (MR) on dendritic cells (DCs), potentially improving antigen uptake, processing, and presentation. While PLGA nanoparticles (NPs) are established vaccine delivery vehicles, the effect of chemical conjugation of…

• T cells
• PLGA
• Nanoparticles
• Polymeric
• Dendritic cells
• Vaccine delivery
• Peptides

27. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro

Luis J. Cruz, Paul J. Tacken, Remco Fokkink, Ben Joosten, Martien Cohen Stuart, Fernando Albericio, Ruurd Torensma, Carl G. Figdor

Antibody-mediated targeting of vaccine components to dendritic cells (DCs) enhances vaccine efficacy, but linking multiple antigens and immune modulators to a single antibody is limited. Slow-release PLGA particles conjugated to DC-specific antibodies could overcome this by delivering large antigen payloads and…

• PLGA
• Dendritic cells
• T cells
• Antigen presentation
• Nanoparticles
• Polymeric
• Vaccine delivery

28. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology

Jaber Emami, Hamed Hamishehkar, Abdolhossien Rouholamini Najafabadi, Kambiz Gilani, Mohsen Minaiyan, Hamid Mahdavi, Hamid Mirzadeh, Amir Fakhari, Ali Nokhodchi

Pulmonary administration offers a route for systemic delivery of therapeutics, especially peptides and proteins, but controlled-release polymer particles are needed. Conventional w/o/w methods for hydrophilic drugs suffer from low encapsulation, protein inactivation, and difficult release control. An oil-in-oil (o/o)…

• PLGA
• Drug delivery
• Polymeric
• Peptides
• Nanocarriers
• Gene delivery
• Nanoparticles

29. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8⁺ T cell-mediated anti-tumor immunity

S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, A. Lavasanifar

Most PLGA-based cancer vaccine studies used foreign model antigens such as ovalbumin (OVA), which are not subject to central/peripheral tolerance and can overestimate therapeutic efficacy. There is a need to evaluate PLGA vaccines against a realistic, clinically relevant self/tumor antigen (TRP2) and to overcome…

• T cells
• PLGA
• Nanoparticles
• Tumour microenvironment
• Polymeric
• Dendritic cells
• Nanocarriers

30. Polymer Nanoparticles for Immunotherapy from Encapsulated Tumor-Associated Antigens and Whole Tumor Cells

C. M. Solbrig, J. K. Saucier-Sawyer, V. Cody, W. M. Saltzman, D. J. Hanlon

Current antitumor vaccines are limited by the small number of defined tumour-associated antigens (TAAs) for most solid tumours and by poor delivery of soluble antigen to dendritic cells (DCs). Autologous whole-tumour lysates contain the full antigenic repertoire, but soluble lysates are unstable and poorly…

• Nanoparticles
• Polymeric
• T cells
• PLGA
• Dendritic cells
• Antigen presentation
• Nanocarriers

31. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles

DNA vaccines are limited by inefficient delivery to antigen-presenting cells (APCs) and lack of adjuvant effect, especially for weakly immunogenic self/tumor antigens. The study addresses this by using cationic PEI-functionalised PLGA microparticles to enhance APC activation and protective anti-tumour immunity…

• Polyethylenimine
• DNA
• PLGA
• Polymeric
• Dendritic cells
• Biodistribution
• Nanocarriers

32. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery

Daqing Wang, Deborah R. Robinson, Glen S. Kwon, John Samuel

Naked plasmid DNA vaccination is largely limited to intramuscular, cutaneous, and intradermal routes because naked DNA is ineffective at crossing mucosal barriers and is rapidly degraded by nucleases. Delivery systems that protect plasmid DNA and target it to antigen-presenting cells are needed for mucosal DNA…

• DNA
• Gene delivery
• Transfection
• PLGA
• Polymeric
• Macrophages
• Nanocarriers

33. Synthesis and Characterization of Acetalated Dextran Polymer and Microparticles with Ethanol as a Degradation Product

Kevin J. Kauffman, Clement Do, Sadhana Sharma, Matthew D. Gallovic, Eric M. Bachelder, Kristy M. Ainslie

Acetalated dextran (Ac-DEX) is a pH-sensitive, biodegradable polymer useful for drug delivery, but it degrades to methanol, which can be toxic at high concentrations or with repeated dosing. A safer analog that degrades to ethanol instead of methanol is needed for high-volume clinical applications such as multiple…

• Polymeric
• PLGA
• Macrophages
• Drug delivery
• Nanocarriers
• Gene delivery
• Nanoparticles